Newsroom

The EIB Reaffirms Confidence in Medincell by Permanently Waiving Two Financial Covenants in its Loan Agreement

February 6, 2025

February 6, 2025

UZEDY® Surges to $117M in Sales in 2024, First Full Year of Commercialization

January 29, 2025

January 29, 2025

2025 Financial Calendar

January 15, 2025

January 15, 2025

Medincell to Join the Euronext SBF 120 Index

December 12, 2024

December 12, 2024

[Replay] Videoconference – H1 2024-25 Results

December 10, 2024

December 10, 2024

Consolidated Half-Year Financial Results

December 10, 2024

December 10, 2024

Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM

December 9, 2024

December 9, 2024

Videoconference and publication of half-year financial results, Tuesday, December 10, 2024

November 29, 2024

November 29, 2024

25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI clinical Phase 3

November 6, 2024

November 6, 2024

New Phase 3 Positive Results for Olanzapine LAI and Real-World Data on UZEDY®

November 4, 2024

November 4, 2024

Participation in Leading Investor Conferences

October 28, 2024

October 28, 2024

New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI

September 23, 2024

September 23, 2024